相关实验视频

Updated: Feb 28, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

作为选择性COX-2抑制剂的Pyrazole衍生物:一个更新的审查

Rajarshi Nath^1,2, Bikram Nandi¹, Arindam Maity²

¹Department of Pharmaceutical Chemistry, Bharat Technology, Uluberia-711316, Howrah, West Bengal, India.

Anti-inflammatory & anti-allergy agents in medicinal chemistry

|February 26, 2026

概括

新的皮拉衍生物显示出作为选择性循环氧化酶-2 (COX-2) 抑制剂治疗炎症的前景. 这项研究审查了它们的合成和活性,为开发更安全的抗炎药物提供了见解.

科学领域:

药用化学医学化学
药物发现药物发现药物发现
药理学药理学是一个学科.

背景情况:

炎症是许多慢性疾病的关键因素,推动了对有效抗炎药物的需求.
目前的非类固醇抗炎药物 (NSAID) 携带不良反应的风险,特别是胃肠道问题,由于非选择性循环氧化酶 (COX) 抑制.
向可诱导的COX-2酶为开发具有更好的安全概况的抗炎药物提供了一种策略.

研究的目的:

为在过去五年中合成的新型pyrazole衍生物提供全面的概述.
评估这些pyrazole衍生物对COX-2的抑制活性.
探索结构-活性关系 (SAR) 和对接洞察力,以开发下一代COX-2抑制剂.

主要方法:

文献综述,重点关注过去5年的皮拉衍生物合成和COX-2抑制活性.
对已识别的化合物的结构-活性关系 (SAR) 的分析.
在基对接研究以了解与COX-2酶的结合相互作用.

主要成果:

鉴定具有显著的COX-2抑制潜力的各种pyrazole衍生物.
阐明了有助于COX-2选择性和强度的关键结构特征.
在设计有效的COX-2抑制剂时展示了pyrazole支架的实用性.

结论:

皮拉衍生物是开发新型选择性COX-2抑制剂的一类有前途的化合物.
经过审查的SAR和对接数据可以指导药物化学家设计下一代抗炎药物.
对基于pyrazole的化合物的进一步研究可能会导致对炎症状况的更安全,更有效的治疗.

关键词:

这是一种COX-2抑制剂.皮拉 (Pyrazole) 是一种可怕的药物.这是一种炎症炎症炎症炎症.结构-活动关系 (SAR).综合合成是一种合成.

更多相关视频

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides CHIPS

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides CHIPS

Published on: June 20, 2014

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...